Bioage Labs, INC 8-K filings

BioAge Labs announced second quarter 2026 financial results, detailing progress in its BGE-102 clinical trials for cardiometabolic and retinal diseases, alongside a robust cash runway through 2029.

BioAge Labs, Inc. successfully concluded its 2026 Annual Meeting of Stockholders, confirming the election of three directors and the ratification of its auditor.

BioAge Labs reports Q1 2026 financial results, highlighting positive BGE-102 clinical data and a strong cash position to fund operations through 2029.

BioAge Labs announced positive interim Phase 1 data for BGE-102, its NLRP3 inhibitor, and completed a $132.3 million follow-on public offering, strengthening its financial position through 2029.

BioAge Labs, a clinical-stage biopharmaceutical company, announced the pricing of an upsized public offering of common stock, expecting to raise approximately $115.0 million in gross proceeds.

BioAge Labs, Inc. announced the expansion of its oral NLRP3 inhibitor BGE-102 development program into ophthalmology, targeting diabetic macular edema with a Phase 1b/2a trial planned for mid-2026.

BioAge Labs announced positive interim Phase 1 data for BGE-102, demonstrating significant reduction in inflammatory markers for cardiovascular risk.

BioAge Labs announced positive interim Phase 1 clinical trial data for BGE-102, a novel NLRP3 inhibitor for cardiovascular risk factors, demonstrating good tolerability, strong target engagement, and high brain penetration.

BioAge Labs announced its third quarter 2025 financial results, highlighting the progression of its BGE-102 and APJ agonist programs and a strong cash position.

BioAge Labs reported Q2 2025 financial results, highlighting significant progress in its clinical pipeline, including the advancement of BGE-102 and APJ agonists, alongside a strong cash position extending through 2029.

BioAge Labs, Inc. announced that its stockholders approved the election of three Class I Directors and ratified KPMG LLP as its independent registered public accounting firm for the 2025 fiscal year at its Annual Meeting held on June 5, 2025.

BioAge Labs, Inc. announced updated anticipated timelines for its NLRP3 and APJ agonist drug development programs, including IND submissions and clinical trial data readouts.

BioAge Labs reports its Q1 2025 financial results, highlights progress on its BGE-102 NLRP3 inhibitor, announces a new collaboration with Lilly, and advances its APJ agonist program.

BioAge Labs announces its full year 2024 financial results, highlights pipeline progress, and unveils new platform partnerships with Novartis and Lilly.

BioAge Labs announced its third quarter 2024 financial results, highlighted by the initiation of a Phase 2 obesity trial and the completion of a successful IPO.

BioAge Labs, Inc. has successfully completed a private placement of common stock with Sofinnova Venture Partners, XI, L.P., raising $10.6 million concurrently with its initial public offering.